A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Clinical trial NCT05514717 · TERMINATED

Trial details

NCT number: NCT05514717
Sponsor: Day One Biopharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2-positive Non-Small Cell Lung Cancer HER2-positive Colorectal Cancer HER2-positive Tumors HER2 Low Breast Cancer

Start date: 2023-01-24
Primary completion: 2026-05-22
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.